Literature DB >> 15156445

Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.

Jae-Hoon Song1, Sook-In Jung, Hyun Kyun Ki, Myung-Hee Shin, Kwan Soo Ko, Jun Seong Son, Hyun-Ha Chang, Shin Woo Kim, Hyuck Lee, Yeon-Sook Kim, Won Sup Oh, Kyong Ran Peck, Anan Chongthaleong, M K Lalitha, Jennifer Perera, Ti Teow Yee, Farida Jamal, Adeeba Kamarulzaman, Celia C Carlos, Thomas So.   

Abstract

To evaluate the clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries, we performed a prospective observational study of 233 cases of adult pneumococcal pneumonia in 9 Asian countries from January 2000 to June 2001. Among 233 isolates, 128 (55%) were not susceptible to penicillin (25.3% were intermediately susceptible, and 29.6% were resistant). Clinical severity of pneumococcal pneumonia was not significantly different between antibiotic-resistant and antibiotic-susceptible groups. Mortality rates among patients with pneumococcal pneumonia caused by penicillin-, cephalosporin-, or macrolide-resistant strains were not higher than those with antibiotic-susceptible pneumococcal pneumonia. Bacteremia and mechanical ventilation were significant risk factors for death, but any kind of antibiotic resistance was not associated with increased mortality due to pneumococcal pneumonia. Outcome of pneumococcal pneumonia was not significantly affected by drug resistance, and current antimicrobial regimens are mostly effective in the treatment of pneumococcal pneumonia, despite the widespread emergence of in vitro resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156445     DOI: 10.1086/420821

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 2.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

3.  Regulatory disincentives for developing antibiotics for common indications.

Authors:  Guy W Amsden
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

4.  Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; V Thamlikitkul; H Wang; T M So; P-R Hsueh; R M Yasin; C C Carlos; P H Van; J Perera
Journal:  Infection       Date:  2012-07-22       Impact factor: 3.553

5.  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.

Authors:  J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez
Journal:  Infection       Date:  2015-09-30       Impact factor: 3.553

Review 6.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

7.  Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study.

Authors:  Weiqiang Chen; Changgui Wu; Zhikui Li; Changqing Bai
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; T M So; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-06       Impact factor: 3.267

10.  Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.

Authors:  Rie Isozumi; Yutaka Ito; Tadashi Ishida; Makoto Osawa; Toyohiro Hirai; Isao Ito; Ko Maniwa; Michio Hayashi; Hitoshi Kagioka; Masataka Hirabayashi; Koichi Onari; Hiromi Tomioka; Keisuke Tomii; Iwao Gohma; Seiichiro Imai; Shunji Takakura; Yoshitsugu Iinuma; Satoshi Ichiyama; Michiaki Mishima
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.